On December 3, 2015 Trillium Therapeutics Inc. (Nasdaq:TRIL; TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, reported it will be providing an update on its SIRPaFc immune checkpoint inhibitor program targeting CD47 at the 57th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Trillium Therapeutics, DEC 3, 2015, View Source [SID:1234508404]). Details of the poster presentation, entitled "SIRPaFc, a CD47- Blocking Cancer Immunotherapeutic, Sensitizes Malignant B cells to MacrophageMediated Destruction," are listed below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date: Sunday December 6, 2015
Time: 6:00 pm – 8:00 pm (EST)
Session: 201. Granulocytes, Monocytes and Macrophages: Poster II
Abstract #: 2191
Presenter: Dr. Natasja Nielsen Viller, Research Scientist
Location: Hall A, Orange County Convention Center
The company will present data demonstrating that its SIRPaFc fusion protein, which targets the CD47 "do not eat" signal, triggers macrophage-mediated phagocytosis of a broad range of human B cell tumors and was effective at controlling the growth of aggressive B lymphoma xenografts in mice. Based on the supportive findings of these and other preclinical studies, Trillium is initiating a phase I dose-escalation study of SIRPaFc in patients with advanced lymphoma and other hematological cancers.
"Patients with cancer clearly benefit from immune checkpoint inhibitors," commented Trillium’s Chief Medical Officer, Dr. Eric Sievers. "We hope to show that interrupting the CD47-SIRPa inhibitory synapse with our decoy receptor will have similarly transformative potential."